|
|
Article: Pharmacology Update: Risedronate (Actonel)-A New Weekly Option for Osteoporosis.(Drug overview)
- Article from:
- Internal Medicine Alert
- Article date:
- September 29, 2002
CopyrightCOPYRIGHT 2002 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Pharmacology Update
Risedronate (Actonel)A New Weekly Option for Osteoporosis
By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD
Risedronate has been approved in a 35 mg once weekly formulation for the treatment of osteoporosis. The drug is currently available as a 5 mg once daily product, but because the drug requires special precautions when it is taken, the once-a-week form may be more convenient. Alendronate (Fosamax), the other currently available oral bisphosphonate, is also available in a once a day and once a week formulation. Risedronate is marketed as Actonel by Proctor & Gamble and Aventis Pharmaceuticals.
...